Related Experiment Video
Updated: Jul 15, 2025
Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging
Published on: December 30, 2016
Background free in vivo29Si MR imaging with hyperpolarized PEGylated silicon nanoparticles
Seung-Hyun Yang1,2, Jiwon Kim3, Tae Geol Lee4
1Department of Radiology, College of Medicine, Yonsei University, Seoul, 03722, Republic of Korea. YMHUH@yuhs.ac.
Abstract:
This study demonstrated the potential of 50 nm PEGylated Si NPs for high-resolution in vivo29Si MR imaging, emphasizing their biocompatibility and water dispersibility. The acquisition of in vivo Si MR images using the lowest reported dose after subcutaneous and intraperitoneal administration opens new avenues for future 29Si MR studies.
Insights
This study shows 50 nm PEGylated silicon nanoparticles (Si NPs) enable high-resolution in vivo 29Si MR imaging. These biocompatible and water-dispersible Si NPs were successfully imaged at a low dose, paving the way for future research.
Area of Science:
- Biomedical Engineering
- Materials Science
- Medical Imaging
Background:
- Silicon nanoparticles (Si NPs) are emerging as contrast agents for magnetic resonance imaging (MRI).
- PEGylation enhances nanoparticle properties like biocompatibility and dispersibility.
- 29Si MRI offers unique advantages for in vivo imaging but requires suitable contrast agents.
Purpose of the Study:
- To evaluate the potential of 50 nm PEGylated Si NPs as contrast agents for high-resolution in vivo 29Si MRI.
- To assess the biocompatibility and water dispersibility of these nanoparticles.
- To determine the feasibility of in vivo imaging at low administered doses.
Main Methods:
- Synthesis and characterization of 50 nm PEGylated Si NPs.
- Assessment of nanoparticle biocompatibility and water dispersibility.
- Administration of Si NPs via subcutaneous and intraperitoneal routes in vivo.
- Acquisition of high-resolution 29Si MR images.
Main Results:
- 50 nm PEGylated Si NPs demonstrated excellent water dispersibility and biocompatibility.
- High-resolution in vivo 29Si MR images were successfully acquired.
- Imaging was achieved using the lowest reported dose for Si NPs.
- Subcutaneous and intraperitoneal administration routes were validated.
Conclusions:
- PEGylated Si NPs are promising contrast agents for high-resolution in vivo 29Si MRI.
- The demonstrated biocompatibility and low-dose efficacy support their clinical translation potential.
- This work establishes a foundation for advanced 29Si MRI applications using Si NPs.
